RxDoctor Payments Data

Steven Ritter, MD

Critical Care Medicine · Poughkeepsie, NYNPI 1073544292

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 59 payments — averaging $30.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • AstraZeneca$375
  • CSL Behring$171
  • Jazz Pharmaceuticals Inc.$165
  • Harmony Biosciences LLC$132
  • Insmed, Inc.$117
  • plus $446 from 12 others

What the payments were for

  • Food & beverage$1,49783%
  • Education$31717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 80th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$223,238
Medicare patients
633
Services billed
2,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)50$118,430
XifaxanRifaximin57$47,645
EliquisApixaban147$41,083
Enoxaparin Sodium241$19,562
FycompaPerampanel24$14,807
Levetiracetam276$14,059
XcopriCenobamate26$13,602
ArexvyRsvpref3 Antigen/As01e/Pf33$10,129
KonvomepOmeprazole/Sodium Bicarbonate31$9,459
Atrovent HfaIpratropium Bromide16$8,046
DapagliflozinDapagliflozin Propanediol11$7,977
NayzilamMidazolam11$7,631
Scopolamine96$7,194
JanuviaSitagliptin Phosphate24$6,880
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam33$5,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$25$47,64557 claims
GSKArexvy$31$10,12933 claims
MerckJanuvia$64$6,88024 claims
AstraZenecaFarxiga$375$4,83513 claims
AbbVieLumigan$407$3,82514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →